Fimasartan Achieving SBP Target (FAST) Study
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 369 participants.
Also called NCT02495324
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 369 participants
- Registry
-
NCT02495324
-
- Other papers using this trial's data
- Effect of Fimasartan versus Valsartan and Olmesartan on Office and Ambulatory Blood Pressure in Korean Patients with Mild-to-Moderate Essential Hypertension: A Randomized, Double-Blind, Active Control, Three-Parallel Group, Forced Titration, Multicenter, Phase IV Study (Fimasartan Achieving Systolic Blood Pressure Target (FAST) Study)
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT02495324. Randomized; quadruple masking; primary purpose treatment. Start 2015-06 (actual); primary completion 2017-05 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Fimasartan Achieving SBP Target (FAST) Study
- Acronym
- FAST
- Condition
- Essential,Hypertension
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Fimasartan
- Intervention (Drug)
- Valsartan
- Intervention (Drug)
- Olmesartan medoxomil
- Lead sponsor
- Boryung Pharmaceutical Co., Ltd
Record details
- Record id
cardio:ct-nct02495324- Content hash
6e63f19ecad9b8c60b6d17cb9d5673130928e18cc66bb022ca1eebeb4ce1419c